Morphological Transformation of Giant-Cell Tumor of Bone After Treatment with Denosumab: A Case Report. uri icon

Overview

abstract

  • CASE: Denosumab, an inhibitor of RANKL (receptor activator of nuclear factor κ-B ligand), was recently introduced for the treatment of giant-cell tumor of bone (GCTB). We describe the clinical, radiographic, and histological features of a GCTB of the spine in a 24-year-old woman that progressed after neoadjuvant treatment with denosumab. Disappearance of the multinuclear osteoclastic giant cells was accompanied by newly formed woven bone, which was deposited in interconnected strands with a prominent fibrovascular stroma that was histologically and radiographically similar to that of an osteoblastoma. CONCLUSION: Pathologists, radiologists, and surgeons should be aware of this post-treatment transformation to avoid misdiagnosis.

publication date

  • January 1, 2016

Research

keywords

  • Bone Density Conservation Agents
  • Denosumab
  • Giant Cell Tumor of Bone
  • Spinal Neoplasms
  • Thoracic Vertebrae

Identity

Scopus Document Identifier

  • 85019797121

Digital Object Identifier (DOI)

  • 10.2106/JBJS.CC.16.00015

PubMed ID

  • 29252651

Additional Document Info

volume

  • 6

issue

  • 3